TianYi Zhang,Baoxi Wang
TianYi Zhang
Severe oral lichenoid reactions associated with immune checkpoint inhibitors [0.03%]
与免疫检查点抑制剂相关的重度口腔黏膜类天疱疮反应
Pauline Hirtz,Jean-Christophe Fricain,Émilie Gérard et al.
Pauline Hirtz et al.
Psoriasis is associated with increased risk of non-exudative age-related macular degeneration [0.03%]
银屑病与非渗出性年龄相关性黄斑变性的发病风险增加有关
Alison M Treichel,Jacky H K Chen,Kaden M Thomas et al.
Alison M Treichel et al.
Half of metastatic CSCC arises from low-stage primaries: A nationwide analysis [0.03%]
半数的转移性CSCC由低分期原发灶发生：全国范围分析
Loes M Hollestein,Antien L Mooyaart,Olivia Frederique Maria Steijlen et al.
Loes M Hollestein et al.
Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results [0.03%]
贝梅西珠单抗治疗汗腺炎的两年疗效：BE HEARD-EXT研究结果
Raj Chovatiya,Afsaneh Alavi,Takuya Miyagawa et al.
Raj Chovatiya et al.
Expert consensus on oral management in autoimmune bullous diseases, erythema multiforme and SJS/TEN [0.03%]
自身免疫性大疱病、黏膜性肢端发红症和SJS/TEN的口腔管理专家共识
Shalini Nayee,Molly Harte,Saskia Ingen-Housz-Oro et al.
Shalini Nayee et al.
Background: Autoimmune bullous diseases (AIBD), Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) and erythema multiforme (EM) often present with clinically similar features in the oral mucosa: classically...
Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study [0.03%]
安木吉利单抗治疗化脓性汗腺炎或掌跖脓疱病的安全性和药代动力学：一项2期临床试验
Johannes S Kern,Simon Francis Thomsen,Georgios Kokolakis et al.
Johannes S Kern et al.
Background: We report the first study of anumigilimab, a novel anti-G-CSFR antibody, in patients with neutrophil-driven skin diseases [hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP)]. ...
Elena Borzova,An Goossens,Enzo Berardesca et al.
Elena Borzova et al.
Occupational eyelid dermatitis (ED) is a much-neglected issue in public health, with important ramifications for patients' quality of life, employment and facial aesthetics. Patients with occupational ED are often younger, male and with an ...
Potential role of tirbanibulin in the management of superficial basal cell carcinoma [0.03%]
替拉班布林在浅表性基底细胞癌治疗中的潜在作用
Cristian Fidanzi,Agata Janowska,Valentina Dini et al.
Cristian Fidanzi et al.
Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial [0.03%]
鲁索利替尼乳膏治疗其他外用药物疗效不佳的成人中度特应性皮炎患者的疗效：一项随机试验
José Manuel Carrascosa,Vimal H Prajapati,H Chih-Ho Hong et al.
José Manuel Carrascosa et al.
Background: In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently control AD signs/symptoms, and escalation to systemic therapy ...